An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression

Cell Reports

Volumn 11, Issue 5, 2015, Pages 715-726

  Zhang, Baochun ^a,b   Calado, DinisPedro ^a,c,d,e   Wang, Zhe ^a,b   Fröhler, Sebastian ^c   Köchert, Karl ^c   Qian, Yu ^b   Koralov, Sergei B ^a,f   Schmidt Supprian, Marc ^a,g   Sasaki, Yoshiteru ^a,h   Unitt, Christine ⁱ   Rodig, Scott ⁱ   Chen, Wei ^c   Dalla Favera, Riccardo ^j,k   Alt, Frederick W ^l   Pasqualucci, Laura ^a,j   Rajewsky, Klaus ^a,c  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h KYOTO UNIVERSITY   (Japan)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k NewYork Presbyterian Hospital   (United States)

^l BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 6; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; BCL6 PROTEIN, MOUSE; DNA BINDING PROTEIN; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CARCINOGENESIS; CONTROLLED STUDY; DEREGULATION; DISEASE MODEL; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; GENE TRANSLOCATION; LARGE CELL LYMPHOMA; LIFESPAN; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DEFICIENCY; DIFFUSE LARGE B CELL LYMPHOMA; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, KNOCKOUT; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-6; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3;

EID: 84933678552     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.03.059     Document Type: Article

References (49)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
3. Basso K., Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv. Immunol. 2010, 105:193-210.
4. Bidère N., Ngo V.N., Lee J., Collins C., Zheng L., Wan F., Davis R.E., Lenz G., Anderson D.E., Arnoult D., et al. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature 2009, 458:92-96.
5. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995, 267:1485-1488.
6. Calado D.P., Zhang B., Srinivasan L., Sasaki Y., Seagal J., Unitt C., Rodig S., Kutok J., Tarakhovsky A., Schmidt-Supprian M., Rajewsky K. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 2010, 18:580-589.
7. Casola S., Cattoretti G., Uyttersprot N., Koralov S.B., Seagal J., Hao Z., Waisman A., Egert A., Ghitza D., Rajewsky K. Tracking germinal center B cells expressing germ-line immunoglobulin gamma1 transcripts by conditional gene targeting. Proc. Natl. Acad. Sci. USA 2006, 103:7396-7401.
8. Cattoretti G., Pasqualucci L., Ballon G., Tam W., Nandula S.V., Shen Q., Mo T., Murty V.V., Dalla-Favera R. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005, 7:445-455.
9. Choi W.W., Weisenburger D.D., Greiner T.C., Piris M.A., Banham A.H., Delabie J., Braziel R.M., Geng H., Iqbal J., Lenz G., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009, 15:5494-5502.
10. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
11. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J.Exp. Med. 2001, 194:1861-1874.
12. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
13. Fabre C., Mimura N., Bobb K., Kong S.Y., Gorgun G., Cirstea D., Hu Y., Minami J., Ohguchi H., Zhang J., et al. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin. Cancer Res. 2012, 18:4669-4681.
14. Gardam S., Sierro F., Basten A., Mackay F., Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008, 28:391-401.
15. Grumont R.J., Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J.Exp. Med. 2000, 191:1281-1292.
16. Häcker H., Tseng P.H., Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat. Rev. Immunol. 2011, 11:457-468.
17. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Müller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
18. He J.Q., Saha S.K., Kang J.R., Zarnegar B., Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J.Biol. Chem. 2007, 282:3688-3694.
19. Iqbal J., Greiner T.C., Patel K., Dave B.J., Smith L., Ji J., Wright G., Sanger W.G., Pickering D.L., Jain S., et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007, 21:2332-2343. Leukemia/Lymphoma Molecular Profiling Project.
20. Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., Niwa A., Chen Y., Nakazaki K., Nomoto J., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
21. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., Van Wier S., Tiedemann R., Shi C.X., Sebag M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
22. Klein U., Casola S., Cattoretti G., Shen Q., Lia M., Mo T., Ludwig T., Rajewsky K., Dalla-Favera R. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat. Immunol. 2006, 7:773-782.
23. Lenz G., Staudt L.M. Aggressive lymphomas. N.Engl. J. Med. 2010, 362:1417-1429.
24. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
25. Mandelbaum J., Bhagat G., Tang H., Mo T., Brahmachary M., Shen Q., Chadburn A., Rajewsky K., Tarakhovsky A., Pasqualucci L., Dalla-Favera R. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010, 18:568-579.
26. Martins G., Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 2008, 26:133-169.
27. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R.C., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
28. Moore C.R., Liu Y., Shao C., Covey L.R., Morse H.C., Xie P. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia 2012, 26:1122-1127.
29. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
30. Neri A., Chang C.C., Lombardi L., Salina M., Corradini P., Maiolo A.T., Chaganti R.S., Dalla-Favera R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 1991, 67:1075-1087.
31. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
32. O'Mahony A., Lin X., Geleziunas R., Greene W.C. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol. Cell. Biol. 2000, 20:1170-1178.
33. Ohinata Y., Payer B., O'Carroll D., Ancelin K., Ono Y., Sano M., Barton S.C., Obukhanych T., Nussenzweig M., Tarakhovsky A., et al. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature 2005, 436:207-213.
34. Pasqualucci L., Compagno M., Houldsworth J., Monti S., Grunn A., Nandula S.V., Aster J.C., Murty V.V., Shipp M.A., Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J.Exp. Med. 2006, 203:311-317.
35. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., Wells V.A., Grunn A., Messina M., Elliot O., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 2011, 43:830-837.
36. Pham L.V., Fu L., Tamayo A.T., Bueso-Ramos C., Drakos E., Vega F., Medeiros L.J., Ford R.J. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. Blood 2011, 117:200-210.
37. Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C., Spina V., Bruscaggin A., Monti S., Cerri M., et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 2011, 118:4930-4934.
38. Saito M., Gao J., Basso K., Kitagawa Y., Smith P.M., Bhagat G., Pernis A., Pasqualucci L., Dalla-Favera R. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007, 12:280-292.
39. Sasaki Y., Derudder E., Hobeika E., Pelanda R., Reth M., Rajewsky K., Schmidt-Supprian M. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006, 24:729-739.
40. Sasaki Y., Calado D.P., Derudder E., Zhang B., Shimizu Y., Mackay F., Nishikawa S., Rajewsky K., Schmidt-Supprian M. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc. Natl. Acad. Sci. USA 2008, 105:10883-10888.
41. Sciammas R., Shaffer A.L., Schatz J.H., Zhao H., Staudt L.M., Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006, 25:225-236.
42. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012, 30:565-610.
43. Srinivas S., Watanabe T., Lin C.S., William C.M., Tanabe Y., Jessell T.M., Costantini F. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001, 1:4.
44. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2010, 2:a000109.
45. Tam W., Gomez M., Chadburn A., Lee J.W., Chan W.C., Knowles D.M. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006, 107:4090-4100.
46. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 1995, 14:2876-2883.
47. Tunyaplin C., Shaffer A.L., Angelin-Duclos C.D., Yu X., Staudt L.M., Calame K.L. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J.Immunol. 2004, 173:1158-1165.
48. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 2003, 100:9991-9996.
49. Ye B.H., Cattoretti G., Shen Q., Zhang J., Hawe N., de Waard R., Leung C., Nouri-Shirazi M., Orazi A., Chaganti R.S., et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 1997, 16:161-170.